Pliant Therapeutics, Inc. (PLRX) — Research Snapshot

As of 2026-10-26. This is a summary of available information, not investment advice.

Recent Catalysts (last ~1–3 months)

Q2 2026 earnings and corporate update (Aug. 11, 2026) — Pliant reported second-quarter results and provided a portfolio update. Highlights included FORTIFY (Phase 1b indication expansion of PLN-101095) "experiencing strong enrollment, progressing ahead of schedule," and the appointment of two seasoned oncology drug-development leaders—Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E.—to the board. R&D expenses fell to $16.7M (from $32.2M year-ago), G&A to $7.1M (from $13.4M), and net loss narrowed to $22.4M (from $43.3M). As of June 30, 2026, the company reported cash, cash equivalents and short-term investments of $159.6 million. [3], [10]